RADNOR, Pa. and PHILADELPHIA, Oct. 15, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and ...
As demand for precision medicine accelerates, CAR T and CAR Treg cell therapies are emerging as crucial tools in the fight against cancer and autoimmune diseases. For Thomas Fellner, PhD, head of ...
Avantor AVTR recently entered into a strategic partnership with BlueWhale Bio to accelerate innovation in CAR-T cell therapy manufacturing. The collaboration merges Avantor’s bioprocessing expertise ...
RADNOR, PA & PHILADELPHIA, PA — Avantor, Inc. (NYSE: AVTR) has entered into a strategic partnership with BlueWhale Bio, a commercial-stage biotechnology firm focused on improving immune cell therapy ...
Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...
Fresenius and Charles River Laboratories are among 18 academic, research, industry and clinical partners that have formed a new European Union-supported consortium to develop an automated, ...
Avantor Inc. (NYSE:AVTR) is one of the best large cap stocks to buy under $20. On October 15, Avantor announced a partnership with BlueWhale Bio, which is a commercial-stage company that transforms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback